By Colin Kellaher
Zosano Pharma Corp. has filed for chapter 11 bankruptcy protection with plans for an orderly wind down of the clinical-stage biopharmaceutical company, it said Thursday.
The Fremont, Calif., company, which last month warned that it would need a substantial cash infusion to stay in business, plans to sell substantially all of its assets during the bankruptcy case, it said.
Zosano in April said it was suspending its M207 lead program in migraine and cutting staff in a bid to preserve cash. The U.S. Food and Drug Administration had previously rejected an application from Zosano seeking approval of M207.
Zosano would continue to operate its business as a "debtor-in-possession" under the bankruptcy court's jurisdiction, it said.
Trading in shares of Zosano, which closed Wednesday at $1.76, was halted premarket on Thursday.
Write to Colin Kellaher at colin.kellaher@wsj.com
$(END)$ Dow Jones Newswires
June 02, 2022 08:19 ET (12:19 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。